Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Review
Immunology
Rosaely Casalegno Garduno, Jan Dabritz
Summary: Studies on the role of CD8(+) T cells in inflammatory bowel disease have shown contradictory outcomes, possibly due to the heterogeneity of the cells. Different subsets of CD8(+) T cells, such as Tc1 and Tc17 cells, may play a role in the pathogenesis of IBD. Regulatory CD8(+) T cells are abundant at sites of inflammation and can exhibit pro-inflammatory features.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biotechnology & Applied Microbiology
Guihua Chen, Jun Shen
Summary: Inflammatory bowel disease (IBD) is a global disease with high morbidity and medical costs. Early diagnosis and intervention are crucial for controlling its progression.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse
Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Biochemistry & Molecular Biology
Shaghayegh Baradaran Ghavami, Hamid Asadzadeh Aghdaei, Dario Sorrentino, Shabnam Shahrokh, Maryam Farmani, Fatemeh Ashrafian, Maria Pina Dore, Shahrbanoo Keshavarz Azizi Raftar, Seyed Mobin Khoramjoo, Mohammad Reza Zali
Summary: Inflammatory bowel diseases (IBDs) are immune-mediated, chronic relapsing diseases with a rising prevalence worldwide. Probiotic bacteria may impact immunomodulation by regulating dendritic cells to produce tolerogenic DCs, which could play a role in the treatment of IBD and associated conditions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Editorial Material
Gastroenterology & Hepatology
Catherine Le Berre, Laurent Peyrin-Biroulet
Summary: The SPIRIT consensus group has agreed that the ultimate therapeutic goal in both CD and UC is to prevent disease impact on patients' lives, including health-related quality of life, disability, and fecal incontinence, as well as prevent complications in the short and long term, such as bowel damage, surgeries, disease extension, extraintestinal manifestations, and dysplasia or cancer. These recommendations will need to be validated in clinical studies before being implemented in disease-modification trials.
Article
Multidisciplinary Sciences
Ryan W. Gan, Diana Sun, Amanda R. Tatro, Shirley Cohen-Mekelburg, Wyndy L. Wiitala, Ji Zhu, Akbar K. Waljee
Summary: This study replicated a machine-learning model's ability to predict acute exacerbations of inflammatory bowel disease (IBD) in a nationally representative cohort, with the random forest model outperforming the logistic regression model.
Review
Medicine, General & Internal
Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano, Giovanni Maconi
Summary: This review summarizes the dermatologic manifestations occurring in patients with inflammatory bowel diseases, including specific manifestations, cutaneous disorders associated with IBDs, reactive mucocutaneous manifestations of IBDs, mucocutaneous conditions secondary to treatment, and manifestations due to nutritional malabsorption. An accurate dermatological examination is crucial in all IBD patients, especially in candidates to biologic therapies where drug-induced cutaneous reactions may be clinically relevant.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Anastasia Katsoula, Georgios Axiaris, Afroditi Mpitouli, Maria Palatianou, Angeliki Christidou, Nikolaos Dimitriadis, Andreas Nakos, Ploutarchos Pastras, Panagiotis Kourkoulis, Pantelis Karatzas, Miltiadis Moutzoukis, Charalampos Zlatinoudis, Athanasios Philippidis, Anastasia Kourikou, Georgios Kokkotis, Antonios Gklavas, Angeliki Machaira, Aikaterini Mantaka, Persefoni Talimtzi, Evaggelia Anagnostopoulou, Ioannis E. Koutroubakis, Ioannis Papaconstantinou, Georgios Bamias, Spilios Manolakopoulos, Nicoletta Mathou, Konstantina Paraskeva, Andreas Protopappas, Eftychia Tsironi, Konstantinos H. H. Katsanos, Dimitrios K. K. Christodoulou, Georgios Papatheodoridis, Georgios Michalopoulos, Georgios Theocharis, Christos Triantos, Ioannis Pachiadakis, Konstantinos Soufleris, Nikolaos Viazis, Gerassimos J. Mantzaris, Georgios Tribonias, Maria Tzouvala, Angeliki Theodoropoulou, Konstantinos Karmiris, Evanthia Zampeli, Spyridon Michopoulos, Anna-Bettina Haidich, Olga Giouleme
Summary: The aim of this study was to validate the content of IBD-Disk in a Greek cohort of IBD patients. The results showed good correlation and consistency between the scores of IBD-Disk and IBD-DI at baseline and follow-up. Female gender and extraintestinal manifestations were significantly associated with a higher IBD-Disk total score. Therefore, the Greek version of IBD-Disk was proven to be a reliable and valid tool for assessing IBD-related disability.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
Mobina Jalalvand, Samaneh Enayati, Maryam Akhtari, Elham Madreseh, Ahmadreza Jamshidi, Elham Farhadi, Mahdi Mahmoudi, Aliakbar Amirzargar
Summary: This meta-analysis aimed to determine the frequency of peripheral blood regulatory T cells (Tregs) in inflammatory bowel disease (IBD) patients. The results showed no significant difference in the frequency of PB Tregs between IBD cases and control subjects. However, the frequency of CD4+CD25+CD127- and CD4+CD25+FoxP3+ Tregs were significantly lower in IBD cases. Additionally, UC cases and active IBD cases showed a significantly lower frequency of Treg cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Cinthia C. Alves, Thais Arns, Maria L. Oliveira, Philippe Moreau, Dinler A. Antunes, Erick C. Castelli, Celso T. Mendes-Junior, Silvana Giuliatti, Eduardo A. Donadi
Summary: In this study, we utilized computational and atomistic approaches to evaluate the structure and dynamics of HLA-G isoforms, the impact of missense mutations at LILRB1/2 genes, and the differential binding of HIF1 to HREs at the HLA-G gene. We also discovered new findings including the instability of HLA-G6 isoforms, the impact of amino acid exchanges at the intracellular domain on HLA-G binding, and the higher affinity of HREs with a guanine at the third position for HIF1. These results shed light on the functional aspects of HLA-G and provide alternative tools to experimental physical methodologies.
Article
Immunology
Carlos A. Fuzo, Thais F. C. Fraga-Silva, Sandra R. Maruyama, Victor A. F. Bastos, Luana A. Rogerio, Nayore T. Takamiya, Pedro V. da Silva-Neto, Vinicius E. Pimentel, Diana M. Toro, Malena M. Perez, Jonatan C. S. de Carvalho, Ingryd Carmona-Garcia, Camilla N. S. Oliveira, Augusto M. Degiovani, Fatima M. Ostini, Leticia F. Constant, Alessandro P. de Amorim, Fernando C. Vilar, Marley R. Feitosa, Rogerio S. Parra, Jose J. R. da Rocha, Omar Feres, Gilberto G. Gaspar, Angelina L. Viana, Ana P. M. Fernandes, Isabel K. F. M. Santos, Elisa M. S. Russo, Cristina R. B. Cardoso, Carlos A. Sorgi, Lucia H. Faccioli, Vania L. D. Bonato, Marcelo Dias-Baruffi
Summary: COVID-19 patients exhibit a wide range of clinical manifestations due to the heterogeneity of the host immune response. By analyzing blood transcriptome, demographic data, clinical aspects, and laboratory findings, we identified perturbations in the blood-leukocyte transcriptional profile that are associated with COVID-19 aggravation and stratify patients according to disease severity. These molecular changes involve processes that inhibit lymphocyte activation and promote neutrophil activation, and the central genes of this unique neutrophil signature are S100A9, ANXA3, CEACAM6, VNN1, OLFM4, IL1R2, TCN1, and CD177.
Article
Dermatology
Ludmilla Figueiredo Fontenelle, Roberto Bueno-Filho, Renata Delfino, Giovanna Stefanne Lopes Barbosa, Eduardo Antonio Donadi, Ana Maria Roselino
Summary: DCP/DP treatment showed similar outcomes in PV and PF patients. Earlier initiation of DCP/DP should be considered for PF patients due to longer disease duration.
ANAIS BRASILEIROS DE DERMATOLOGIA
(2023)
Letter
Immunology
Nivia Maria Rodrigues Arrais, Ricardo Fernando Arrais, Marilia Costa Coelho, Neifi Hassan Saloum Deghaide, Eduardo Antonio Donadi, Claudia Rodrigues Souza Maia, Maria Isabel de Moraes-Pinto
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2023)
Article
Virology
Jonatan C. S. de Carvalho, Pedro V. da Silva-Neto, Diana M. Toro, Carlos A. Fuzo, Viviani Nardini, Vinicius E. Pimentel, Malena M. Perez, Thais F. C. Fraga-Silva, Camilla N. S. Oliveira, Augusto M. Degiovani, Fatima M. Ostini, Marley R. Feitosa, Rogerio S. Parra, Jose J. R. da Rocha, Omar Feres, Fernando C. Vilar, Gilberto G. Gaspar, Isabel K. F. M. Santos, Ana P. M. Fernandes, Sandra R. Maruyama, Elisa M. S. Russo, Vania L. D. Bonato, Cristina R. B. Cardoso, Marcelo Dias-Baruffi, Lucia H. Faccioli, Carlos A. Sorgi
Summary: COVID-19 is associated with immune dysregulation, and glucocorticoids (GCs) have attracted attention for their role in inhibiting pro-inflammatory cytokines. The endocannabinoid (eCB) system also regulates immune response. However, the effect of GCs on the lipid pathway in COVID-19 therapy is still unknown.
Article
Medicine, General & Internal
Rogerio Serafim Parra, Sandro da Costa Ferreira, Vanessa Foresto Machado, Cintia Maura Caseiro Nigro, Jose Joaquim Ribeiro da Rocha, Luiz Ernesto de Almeida Troncon, Omar Feres
Summary: This study aimed to analyze Brazilian patients with inflammatory bowel diseases (IBD) perception regarding access to high-cost drugs in the public health care system. The results showed that most patients were unable to obtain biological drugs within one year. This study highlights the need for improvement in the healthcare system to ensure the correct supply of medication.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Rogerio Serafim Parra, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Sergio Figueiredo de Lima Junior, Manoel Alvaro Lins Neto, Terry Rocha de Medeiros, Francesca Maia Faria, Marley Ribeiro Feitosa, Cintia Maura Caseiro Nigro, Omar Feres
Summary: This study presents a case series of vasculitis induced by anti-TNF therapy in patients with inflammatory bowel disease (IBD). Five patients with leukocytoclastic vasculitis (LCV) were identified, all of whom were white, female, and non-smokers. The onset of LCV occurred at an average of 30.8 months after starting biologic therapy, and all patients showed significant improvement after discontinuation of anti-TNF therapy and treatment with oral steroids.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Leticia Rodrigues de Souza, Daniela Oliveira Magro, Fabio Vieira Teixeira, Rogerio Serafim Parra, Eron Fabio Miranda, Omar Feres, Rogerio Saad-Hossne, Giedre Soares Prates Herrerias, Renato Mitsunori Nisihara, Claudio Saddy Rodrigues Coy, Ligia Yukie Sassaki, Paulo Gustavo Kotze
Summary: Despite some variability in ADA concentrations, higher concentrations are associated with sustained efficacy and low levels can lead to loss of response in CD patients. This study aimed to correlate serum ADA concentrations with clinical and endoscopic activity in CD patients. The results showed no difference in serum ADA concentrations in active or remission CD patients, suggesting no correlation between ADA concentrations and disease activity.
Article
Biochemistry & Molecular Biology
Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Luisa Leite Barros, Jane Oba, Carlos Walter Sobrado Junior, Aytan Miranda Sipahi, Olivia Duarte de Castro Alves, Tomas Navarro-Rodriguez, Rogerio Serafim Parra, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Cristina Flores, Andrea Vieira, Christianne Damasceno Arcelino do Ceara, Natalia Sousa Freitas Queiroz, Aderson Omar Mourao Cintra Damiao
Summary: Therapeutic drug monitoring (TDM) is important in optimizing response to anti-tumor necrosis factor drugs and preventing inadequate drug exposure. This study aimed to describe the remission rates of Brazilian inflammatory bowel disease (IBD) patients at six months using a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels. The results showed that proactive TDM was associated with a high persistence rate of 82.9% and favorable remission rates at six months.
Article
Cell Biology
Diana Mota V. Toro, Pedro V. da Silva-Neto, Jonatan C. S. A. de Carvalho, Carlos A. M. Fuzo, Malena M. Perez, Vinicius E. Pimentel, Thais F. C. Fraga-Silva, Camilla N. S. R. Oliveira, Glaucia R. Caruso, Adriana F. L. Vilela, Pedro V. Nobre-Azevedo, Thiago V. Defelippo-Felippe, Jamille G. M. M. Argolo, Augusto M. Degiovani, Fatima M. R. Ostini, Marley R. S. Feitosa, Rogerio S. C. Parra, Fernando C. G. Vilar, Gilberto G. Gaspar, Jose J. R. da Rocha, Omar P. Feres, Gabriel P. Costa, Sandra R. C. Maruyama, Elisa M. S. Russo, Ana Paula M. Fernandes, Isabel K. F. M. Santos, Adriana T. Malheiro, Ruxana T. Sadikot, Vania L. D. Bonato, Cristina R. B. Cardoso, Marcelo Dias-Baruffi, Atila A. Trape, Lucia H. A. Faccioli, Carlos A. Sorgi, ImmunoCovid Consortium Grp
Summary: SARS-CoV-2 infection leads to distinct disease patterns with significant changes in host regulatory responses. Severe cases suffer from lung inflammation and systemic effects, while critically ill patients experience a lipid storm that affects inflammation and tissue damage. Sphingolipids play critical roles in various cellular processes and may serve as potential biomarkers and therapeutic targets for COVID-19.
Article
Gastroenterology & Hepatology
Adriana Zanoni Dotti, Daniela Oliveira Magro, Eduardo Garcia Vilela, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Flavio Steinwurz, Marjorie Argollo, Nayara Salgado Carvalho, Jose Miguel Luz Parente, Murilo Moura Lima, Rogerio Serafim Parra, Ramir Luan Perin, Cristina Flores, Eloa Marussi Morsoletto, Sandro da Costa Ferreira, Juliano Coelho Ludvig, Roberto Luiz Kaiser, Mikaell Alexandre Gouvea Faria, Guilherme Mattioli Nicollelli, Adriana Ribas Andrade, Natalia Sousa Freitas Queiroz, Paulo Gustavo Kotze
Summary: This study demonstrates the effectiveness and safety of vedolizumab as a first-line biological agent in patients with mild-to-moderate Crohn's disease.
CROHNS & COLITIS 360
(2023)
Article
Gastroenterology & Hepatology
Ramir Luan Perin, Daniela Oliveira Magro, Adriana Ribas Andrade, Marjorie Argollo, Nayara Salgado Carvalho, Aderson Omar Moura Cintra Damiao, Adriana Zanoni Dotti, Sandro da Costa Ferreira, Cristina Flores, Juliano Coelho Ludvig, Rodrigo Bremer Nones, Natalia Sousa Freitas Queiroz, Rogerio Serafim Parra, Flavio Steinwurz, Fabio Vieira Teixeira, Paulo Gustavo Kotze
Summary: The study demonstrated the efficacy and safety of tofacitinib in patients with ulcerative colitis from Latin America, which was consistent with previous studies from other countries and meta-analyses.
CROHNS & COLITIS 360
(2023)